Nessan Birmingham
Direttore/Membro del Consiglio presso Stylus Medicine, Inc.
Provenienza dei contatti di primo grado di Nessan Birmingham
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Stylus Medicine, Inc.
 Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures.
5
| Holding Company | Medical Specialties | 5 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Nessan Birmingham tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor Private Equity Investor | |
| PREVAIL THERAPEUTICS INC. | Biotechnology | Corporate Officer/Principal | |
| CELGENE | Biotechnology | Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin | |
| Princeton University | College/University | Undergraduate Degree | |
Design Pharmaceuticals, Inc.
 Design Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Design Pharmaceuticals, Inc. harnesses nature's chemistry to develop breakthrough therapeutics. The company is based in Cambridge, MA. The company uses engineering-inspired biotechnologies to redesign the process of small molecule-based drug discovery and development, saving time and costs. The company's platform is based on ultrahigh-throughput technologies that biomine and test drug-like molecules from nature at unprecedented speed and scale on hundreds of GPCR targets simultaneously. Design Pharmaceuticals' cell-free biosynthesis eliminates the inherent limitations of traditional chemistry or using platforms based on live production strains, further accelerating lead compound optimization. The company's business model aims to build a continuously growing portfolio of joint development and license agreements with pharma partners. The company was founded by Dirk Löffert, Cosmas Giallourakis, Marnix Medema, Rob Nicol, Noah W. Palm, Michael Jewett, Andrew Griffiths. Dirk Löffert has been the CEO since incorporation. | Miscellaneous Commercial Services | Founder | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree | |
| New Jersey Medical School | College/University | Doctorate Degree | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
| Giappone | 2 |
Settori
| Consumer Services | 4 |
| Health Technology | 4 |
| Finance | 3 |
| Commercial Services | 2 |
Posizioni
| Director/Board Member | 5 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 2 |
| Private Equity Investor | 2 |
| Masters Business Admin | 1 |
Contatti più connessi
| Insiders | |
|---|---|
| Emily Minkow | 6 |
| Cosmas Giallourakis | 6 |
| Ami Bhatt | 1 |
| Patrick Hsu | 1 |
| Josh Resnick | 1 |
- Borsa valori
- Insiders
- Nessan Birmingham
- Connessioni Società
